A panelist discusses how graft-vs-host disease (GVHD) manifests through a complex constellation of symptoms affecting ...

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...

The efficacy of IVIG in preventing GvHD has not been definitely demonstrated clinically. Using a xenogeneic model of GvHD in NOD/SCID/γc− (NSG) mice, we showed that weekly administration of ...

The rash can often become widespread and precede the onset of gastrointestinal or liver symptoms.3 Chronic GvHD also tends to start with a burning rash on the same parts of the body, although it ...

Itolizumab showed significant long-term benefits in acute GVHD, improving complete response duration and failure-free survival. Equillium, Inc. seeks Breakthrough Therapy designation and Accelerated ...

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder. The US regulator has cleared ...